This review explores motilins physiological functions, mechanisms of action, cellular targets, developmental context, and clinical implications, underscoring its centrality in digestive physiology and its emerging role in gastrointestinal pharmacology
In patients taking JANUMET XR whose eGFR later falls below 45 mL/min/1.73 m2, assess the benefit risk of continuing therapy and limit dose of the sitagliptin component to 50 mg once daily
MAS825, an IL-1 blocker that also blocks IL-18, another cytokine, has previously been studied for COVID-19 infections, and is now in a phase II trial investigating its efficacy for HS
To view a copy of this licence, visit About this article Cite this article Feng, P., Sheng, X., Ji, Y